|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study indicates that in LYP the atypical hyperchromatic cerebriform mononuclear cells of type B invariably constitute a monoclonal T-cell population whereas the atypical CD30 positive type A cells represent a proliferation of cells of non-B, non-T-cell lineage.
|
1850775 |
1991 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings are significant for several reasons: 1) they demonstrate the common clonal origin of lymphomatoid papulosis and CD30+ large-cell lymphoma or mycosis fungoides occurring in individual patients; 2) they confirm that co-migrating PCR/DGGE bands exhibit identical nucleotide sequences; and 3) they provide a method for determining the sequence of a tumor-derived TCR-gamma gene rearrangement in early lesions containing a low tumor clone density.
|
7615976 |
1995 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results support the hypothesis that (1) primary cutaneous CD30+ LPDs (including LyP) and primary nodal ALCL are distinct diseases that differ in clinical behavior and pathogenesis and (2) differential expression of t(2;5) can help to distinguish between primary cutaneous CD30+ LPDs and ALCL of nodal origin.
|
8605362 |
1996 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of t(2;5) in a subset of CD30+ cutaneous lymphoma and LP may indicate a common pathogenesis with a subset of anaplastic nodal lymphoma.
|
8701987 |
1996 |
|
Lymphomatoid Papulosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To determine the role of the t(2;5) translocation in these diseases, we developed a DNA-based polymerase chain reaction (PCR)/Southern blot assay to detect this translocation at the genomic level in lymphomatoid papulosis (14 cases), primary cutaneous CD30+ large cell lymphoma of T-lineage (10 cases) and Hodgkin's disease (13 cases).
|
8781433 |
1996 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis and cutaneous CD30+ lymphoma.
|
8806956 |
1996 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary cutaneous CD30 (Ki-1)+ large cell lymphoma (KiL) and lymphomatoid papulosis (LyP) type A are collectively termed as primary cutaneous CD30-positive lymphoproliferative disorders.
|
8941669 |
1996 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that, in contrast to primary cutaneous CD30-negative pleomorphic large T-cell lymphomas, the neoplastic cells in most primary cutaneous CD30-positive (anaplastic) large T-cell lymphomas and lymphomatoid papulosis have a unique CD4+, CD8-, cytotoxic T-cell phenotype.
|
9347791 |
1997 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This points to a molecular aetiology of primary cutaneous ALC lymphomas and LyP distinct from that of extracutaneous CD30+ lymphoproliferative disease.
|
9415224 |
1997 |
|
Lymphomatoid Papulosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The genes encoding the T-cell receptor (TCR) variable beta (TCRBV) regions were studied in skin biopsy samples from 24 patients with cutaneous T-cell lymphomas (CTCL), i.e. mycosis fungoides (n = 7), Sézary syndrome (n = 4), lymphomatoid papulosis (n = 3) and large cell CTCL with (n = 3) or without (n = 7) CD30 expression.
|
9536217 |
1998 |
|
Lymphomatoid Papulosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aggregate results of these studies indicate that the t(2;5) translocation or other somatic mutations resulting in inappropriate expression of ALK are involved rarely if at all in the pathogenesis of Hodgkin's disease, but may be present in about 10% of cases of lymphomatoid papulosis and 20% of cases of CD30+ primary cutaneous large cell lymphoma.
|
9638979 |
1998 |
|
Lymphomatoid Papulosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this article is to review the pathologic and clinical spectrum of ALCL, including the borderline with Hodgkin's disease and lymphomatoid papulosis and to discuss the use of the t(2;5) in better defining a more specific molecular pathologic entity within this group of diseases with CD30 expression.
|
9894470 |
1999 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-eight LyP lesions were classified histologically and analysed further with immunostaining for CD3 and CD30.
|
10025972 |
1998 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nine of 17 cases showed the characteristic clinical and histological features as well as clinical behavior of well defined types of CTCL, such as mycosis fungoides (2 cases), pagetoid reticulosis (2 cases), lymphomatoid papulosis (2 cases), and CD30+ large T cell lymphoma (2 cases), all of which usually express a CD4+ T cell phenotype, and 1 case of subcutaneous panniculitis-like T cell lymphoma.
|
10433941 |
1999 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) is a chronic, recurrent lymphoproliferative disorder of the skin that belongs to the group of primary cutaneous CD30-positive T-cell lymphomas.
|
11168749 |
2001 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) is defined as a recurrent self-healing papulonodular eruption with the histological features of a (CD30+) cutaneous T-cell lymphoma.
|
11531801 |
2001 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical stains for CD8, CD30, CD79 and CLA may be valuable tools in the differential diagnosis between PLEVA and LyP.
|
11553311 |
2001 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our objective is to understand the mechanism of progression of lymphomatoid papulosis (LyP) to CD30+ systemic lymphoma.
|
11594583 |
2001 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
To definitively clarify whether the large atypical CD30(+) cells in LyP without associated lymphoma all belong to the same clone or represent individually rearranged T cells, we analyzed the T-cell receptor-gamma rearrangements of single CD30+ as well as of single CD30- cells isolated from 14 LyP lesions of 11 patients.
|
12091351 |
2002 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To definitively clarify whether the large atypical CD30(+) cells in LyP without associated lymphoma all belong to the same clone or represent individually rearranged T cells, we analyzed the T-cell receptor-gamma rearrangements of single CD30+ as well as of single CD30- cells isolated from 14 LyP lesions of 11 patients.
|
12091351 |
2002 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While lesions of lymphomatoid papulosis are definitionally positive for CD30, their ability to express CD56 has not been formally studied.
|
12150138 |
2002 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Purportedly, CD30 is useful in the differential diagnosis between insect bites and lymphomatoid papulosis.
|
12826883 |
2003 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that expression of c-kit receptor is exceedingly rare among CD30+ lymphomas and lymphomatoid papulosis, suggesting that c-kit receptor is unlikely to be an appropriate target for therapeutic options such as imatinib in patients with these tumors.
|
15105813 |
2004 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we determined that two allelic forms of the CD30 promoter microsatellite repressive element, designated 30M377 and 30M362, are associated with the development of lymphomatoid papulosis and CD30+ lymphomas in lymphomatoid papulosis patients, respectively.
|
15894695 |
2005 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30+ cutaneous lymphoproliferative disorders include lymphomatoid papulosis (LyP) and anaplastic large cell lymphoma (ALCL).
|
16412208 |
2006 |